MAP3K7 and diabetes mellitus: To further validate TAK1 as a candidate therapeutic target in the amelioration of diabetes, we used a potent and selective TAK1 kinase inhibitor—5Z-7-oxozeaenol (OZ) to treat female NOD mice at the onset of diabetes with doses of 15 μg or 30 μg/mouse.